Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Mar 2023. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5181446012 | Valproate sodium 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5181447015 | Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5181448013 | Product containing precisely sodium valproate 333.3 milligram and valproic acid 145.14 milligram/1 sachet prolonged-release oral granules (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Is a | Valproic acid only product in oral dose form | true | Inferred relationship | Some | ||
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has manufactured dose form | Prolonged-release oral granules (dose form) | true | Inferred relationship | Some | ||
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has unit of presentation | Sachet (unit of presentation) | true | Inferred relationship | Some | ||
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Plays role | Anticonvulsant therapeutic role (role) | true | Inferred relationship | Some | ||
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has precise active ingredient | Valproic acid (substance) | true | Inferred relationship | Some | 1 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has basis of strength substance (attribute) | Valproic acid (substance) | true | Inferred relationship | Some | 1 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has presentation strength denominator unit (attribute) | Sachet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has precise active ingredient | Sodium valproate | true | Inferred relationship | Some | 2 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has basis of strength substance (attribute) | Sodium valproate | true | Inferred relationship | Some | 2 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Sodium valproate 333.3 mg and valproic acid 145.14 mg prolonged-release oral granules sachet | Has presentation strength denominator unit (attribute) | Sachet (unit of presentation) | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
FHIR